Stifel Financial Corp Cuts Stock Position in Evolent Health, Inc. (NYSE:EVH)

Stifel Financial Corp decreased its stake in Evolent Health, Inc. (NYSE:EVH) by 52.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,041 shares of the technology company’s stock after selling 13,254 shares during the quarter. Stifel Financial Corp’s holdings in Evolent Health were worth $341,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Point72 Asset Management L.P. boosted its stake in shares of Evolent Health by 1,948.5% in the third quarter. Point72 Asset Management L.P. now owns 1,495,385 shares of the technology company’s stock worth $42,289,000 after acquiring an additional 1,422,385 shares during the last quarter. Polar Asset Management Partners Inc. purchased a new position in Evolent Health in the 3rd quarter valued at $6,804,000. Point72 Asia Singapore Pte. Ltd. boosted its stake in Evolent Health by 2,471.9% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 6,507 shares of the technology company’s stock worth $184,000 after purchasing an additional 6,254 shares during the last quarter. Bellevue Group AG grew its holdings in shares of Evolent Health by 59.9% during the third quarter. Bellevue Group AG now owns 2,670,050 shares of the technology company’s stock worth $75,509,000 after buying an additional 1,000,215 shares in the last quarter. Finally, Eventide Asset Management LLC raised its position in shares of Evolent Health by 1.7% in the third quarter. Eventide Asset Management LLC now owns 3,804,104 shares of the technology company’s stock valued at $107,580,000 after buying an additional 64,985 shares during the last quarter.

Evolent Health Trading Down 1.9 %

Shares of EVH stock opened at $11.13 on Friday. Evolent Health, Inc. has a 1-year low of $10.53 and a 1-year high of $35.00. The firm has a market cap of $1.30 billion, a PE ratio of -12.23 and a beta of 1.45. The company has a 50-day moving average of $15.20 and a two-hundred day moving average of $21.75. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.04 and a quick ratio of 1.04.

Analyst Ratings Changes

Several analysts recently issued reports on EVH shares. Royal Bank of Canada reaffirmed an “outperform” rating and set a $20.00 price objective on shares of Evolent Health in a research note on Tuesday, November 12th. Stephens lowered Evolent Health from an “overweight” rating to an “equal weight” rating and dropped their price target for the company from $38.00 to $16.00 in a research report on Friday, November 8th. KeyCorp assumed coverage on Evolent Health in a research report on Friday, October 11th. They set an “overweight” rating and a $35.00 price objective on the stock. Barclays dropped their target price on Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a report on Monday, November 11th. Finally, Citigroup reduced their price target on Evolent Health from $33.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. One analyst has rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $26.18.

Evolent Health Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.